20-Mar-2010
Subscription Info
|
Institutional Access
|
Browse the Faculties
|
Free Trial
|
Take a Tour
|
Top 10s
|
Advanced Search
|
About
|
Faculty Member List
|
Associate FMs
|
F1000 Reports
Search
All F1000
Oncology
Browse
ALL OF MEDICINE
Oncology
Breast Diseases: Benign & Malignant
Cancer in the Elderly
Genitourinary Cancers
Gynecological Cancers
Head & Neck Cancers
Oncology Agents
Pediatric Oncology
Sarcomas
Supportive & Palliative Cancer Care
Related Sections
Adrenal Cortex
Gastrointestinal Cancers
Leukemia & Proliferative Disorders of Hematic Cells
Lung Cancer
Lymphomas & Myelomas
Multiple Endocrine Disorders & Neoplasias
Neuro-Oncology
Skin Cancers (inc. Melanoma & Lymphoma)
selected for
My F1000
Browse > Oncology
Current Top 10 by F1000 Factor
/
All Time Top 10 by F1000 Factor
/
Most viewed
(from all journals)
/
Most viewed
(from specialty journals)
/
Hidden jewels
Page 1 of 81. Select Page:
1
2
3
4
5
6
7
8
9
10
>>
Display
10
/
20
/
50
papers per page
printer friendly
10 per page
20 per page
50 per page
any date
past 7d
past 14d
past 30d
past 60d
past 90d
past 180d
past 1y
past 2y
past 5y
all papers
hypotheses
new findings
confirmations
tech advances
controversial
refutation
dissenting
new on F1000
newly evaluated
F1000 factor
most evaluations
this page
selected articles
to
EndNote
Ref. Manager
RefWorks
Bibtex
ProCite
email [
Help
]
Recommended
F1000 Factor
3.0
Confirmation
Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation.
Ell K, Vourlekis B, …, Russell C, Palinkas LA
Cancer
2009 Oct 1
115
(19):4606-15 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Kelly Biegler and Lari Wenzel
Evaluated 19 Mar 2010
Must Read
F1000 Factor
6.0
New Finding
Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor.
Onori P, Wise C, …, Dostal DE, Glaser SS
Int J Cancer
2009 Nov 10 [
abstract on PubMed
] [
related articles
] [
full text
]
Selected by
| Mellanie White and Gianfranco Alpini
Evaluated 19 Mar 2010
Recommended
F1000 Factor
3.0
New Finding
EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.
Dojcinov SD, Venkataraman G, …, Pittaluga S, Jaffe ES
Am J Surg Pathol
2010 Mar
34
(3):405-17 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Fabio Facchetti
Evaluated 19 Mar 2010
Recommended
F1000 Factor
3.0
Changes
Clinical Practice
Confirmation
Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole.
Cowen EW, Nguyen JC, …, Turner ML, Fox LP
J Am Acad Dermatol
2010 Jan
62
(1):31-7 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Erin Huiras Amerson and Toby Maurer
Evaluated 19 Mar 2010
Must Read
F1000 Factor
6.0
New Finding
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.
Ladenson PW, Kristensen JD, …, Baxter JD, Angelin B
N Engl J Med
2010 Mar 11
362
(10):906-16 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Krystian Jazdzewski and Sissy Jhiang
Evaluated 18 Mar 2010
Must Read
F1000 Factor
6.0
New Finding
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.
Cantara S, Capezzone M, …, Montanaro A, Pacini F
J Clin Endocrinol Metab
2010 Mar
95
(3):1365-9 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Llanyee Liwanpo and Jerome Hershman
Evaluated 18 Mar 2010
Recommended
F1000 Factor
3.0
Confirmation
Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis.
Riquet M, Achour K, …, Dujon A, Cazes A
Ann Thorac Surg
2010 Mar
89
(3):870-5 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Pyng Lee
Evaluated 17 Mar 2010
Must Read
F1000 Factor
6.0
Changes
Clinical Practice
New Finding
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM, Mo D, …, Woodmansee WW, International HypoCCS Advisory Board
J Clin Endocrinol Metab
2010 Feb
95
(2):630-8 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Marina Cardinaletti and Marco Boscaro
Evaluated 17 Mar 2010
Must Read
F1000 Factor
6.0
Confirmation
Duration of androgen suppression in the treatment of prostate cancer.
Bolla M, de Reijke TM, …, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group
N Engl J Med
2009 Jun 11
360
(24):2516-27 [
abstract on PubMed
] [
related articles
] [
FREE full text
]
Selected by
| Kate Linton and James Catto
Evaluated 17 Mar 2010
Recommended
F1000 Factor
3.0
Confirmation
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM, Lopez N, …, Omry G, Larson S
Thyroid
2010 Mar
20
(3):257-63 [
abstract on PubMed
] [
related articles
] [
full text
] [
order article
]
Selected by
| Barry Shulkin
Evaluated 17 Mar 2010
top of page
Page 1 of 81. Select Page:
1
2
3
4
5
6
7
8
9
10
>>
Display
10
/
20
/
50
papers per page
© 2010 Medicine Reports Ltd unless otherwise stated.
< info@f1000.com >
Terms and conditions
Legal info
selected for 
Confirmation
New Finding
top of page